Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Steps into Diabetes Market with 7th DPP-4 Inhibitor Onglyza
July 9, 2013
- CMIC Subsidiary SSI to Set Up Committee to Investigate Suspected Clinical Data Manipulation
July 9, 2013
- Ethical Drug Sales Up 3.3% in May: Crecon Report
July 9, 2013
- Kyorin to Merge 2 Domestic Development Sites in Tochigi Prefecture
July 8, 2013
- Daiichi Sankyo to Promote Osteoporosis Treatment Pralia with Focus on Appropriate Use
July 5, 2013
- Over 60% of Cancer Patients Aware of Generic Cancer Treatment Options: Sawai Survey
July 5, 2013
- Fujifilm to Begin PIII Study of Personalized Peptide Cancer Vaccine
July 5, 2013
- AY Pharmaceuticals Starts Operations, Yoshindo Bolsters Sales, Marketing System
July 5, 2013
- Hanshin DP Holdings, Medical System Network Establish New JV to Support Efficient Distribution
July 5, 2013
- Importance of Personal Relationships, Low Use of Generics Contribute to Persistence of SOV Model in Japan, but Change is Likely
July 5, 2013
- MTPC Begins Construction of New Head Office Building, Expects Completion in January 2015
July 4, 2013
- Generic Industry Needs to Produce 30 Billion More Tablets to Meet 60% Generic Share Goal: Sawai President
July 4, 2013
- Out-Licensed OAB Treatment Imidafenacin Launched in South Korea: Kyorin Holdings
July 4, 2013
- Low-Dose Lunabell Approved
July 4, 2013
- Manipulation of BMI Data in Kobayashi Pharmaceutical’s Anti-Obesity Drug Clinical Study Suspected
July 3, 2013
- Sandoz to Ratchet Up Promotions for General Practitioners, Dispensing Pharmacies
July 3, 2013
- Latuda Approved for Major Depressive Episodes Associated with Bipolar I Disorder in the US: DSP
July 3, 2013
- Japanese Society of Chemotherapy Joins Hands with Pharmas, Govt to Spur New Antibiotic Development
July 2, 2013
- DSP Adopts Tokyo-Osaka Two Head Office System
July 2, 2013
- Takeda Withdraws European MAA for Anemia Treatment Peginesatide Following Voluntary Recall in US
July 2, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…